Impact of Clinical Characteristics of Individual Metabolic Syndrome on the Severity of Insulin Resistance in Chinese Adults by Hsieh, Chang-Hsun et al.
INTRODUCTION
According to the Taiwan Department of Health, the cumu-
lative death rates from coronary artery disease, stroke, and
diabetes are 152 cases per 100,000/yr, which nearly equals
the death rate from malignancies. These ‘modern diseases’
are a huge burden, not only to the patients themselves, but
also to their families and society. This alarming trend is not
unique to Taiwan, and has been reported to occur in many
other parts of the world. Therefore, the prevention and early
detection of coronary heart disease and diabetes has become
a major public health issue. The well-known risk factors for
these diseases include excess body weight, hypertension, hy-
perlipidemia, and hyperglycemia. Indeed, the clustering of
these risk factors was first noted in 1966 (1). In 1988, Reaven
introduced the term Syndrome X, which consisted of hyper-
insulinemia, hypertension, dyslipidemia, hyperglycemia, and
resistance to insulin-mediated glucose uptake (2). He suggest-
ed that insulin resistance (IR) plays an important role in the
etiology and clinical course of patients with diabetes mellitus,
hypertension, and coronary heart disease (3). In 1998, the
World Health Organization (WHO) also recognized the im-
portance of this clustering and further defined the clinical
characteristics of the ‘metabolic syndrome’ (MetS) (4). How-
ever, such criteria are not practical for routine clinical use
because one of the major criteria, IR, requires measurement
by a hyperinsulinemic euglycemic clamp. Therefore, the Na-
tional Cholesterol Education Program Adult Treatment Panel
III (ATP III) provided a simpler definition in 2001, in the
hope that it could be used even in general practice (5). It had
been shown that patients with MetS, as defined by either
WHO or ATP III criteria, have more severe IR as compared
to the general population (6, 7). However, the cut-off values
of these diagnostic criteria were originally determined arbi-
trarily, have never been stratified according to a weighted clin-
ical effect, and may vary in different ethnic groups. Moreover,
it is unknown which of the five clinical characteristics amongst
the ATP III criteria, if any, is related to more severe IR. 
In the current study, we measured IR directly by an insulin
suppression test (IST). Subjects were placed into quartiles
based on the level of each of the MetS clinical characteristics.
Then, the steady state plasma glucose (SSPG) level resulting
from the IST was compared between the different quartiles
representing one clinical characteristic as well as between all
the different clinical characteristics. Furthermore, factor anal-
ysis (8, 9), a multivariate statistical tool, could reduce a con-
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Impact of Clinical Characteristics of Individual Metabolic Syndrome
on the Severity of Insulin Resistance in Chinese Adults
The impact the metabolic syndrome (MetS) components on the severity of insulin
resistance (IR) has not been reported. We enrolled 564 subjects with MetS and
they were divided into quartiles according to the level of each component; and an
insulin suppression test was performed to measure IR. In males, steady state plas-
ma glucose (SSPG) levels in the highest quartiles, corresponding to body mass
index (BMI) and fasting plasma glucose (FPG), were higher than the other three
quartiles and the highest quartiles, corresponding to the diastolic blood pressure
and triglycerides, were higher than in the lowest two quartiles. In females, SSPG
levels in the highest quartiles, corresponding to the BMI and triglycerides, were higher
than in all other quartiles. No significant differences existed between genders, other
than the mean SSPG levels in males were greater in the highest quartile correspond-
ing to BMI than that in the highest quartile corresponding to HDL-cholesterol levels.
The factor analysis identified two underlying factors (IR and blood pressure factors)
among the MetS variables. The clustering of the SSPG, BMI, triglyceride and HDL-
cholesterol was noted. Our data suggest that adiposity, higher FPG and triglyceride
levels have stronger correlation with IR and subjects with the highest BMI have the
highest IR.
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siderable number of inter-correlated variables to a smaller
set that accounts for most of the variances between the data.
By this mean, a set of dimensions (sometimes called factors)
which are not easily observed in the original variable could
be identified. Therefore, it was also used to investigate which
of MetS factors are related to IR (SSPG levels).Thus, we are
able to determine the severity of IR between the quartiles
representing each clinical characteristic, but also determine
which clinical characteristic of MetS was associated with the
most severe IR when compared with other clinical charac-
teristics within the Chinese population.
MATERIALS AND METHODS
Subjects
Five hundred sixty four subjects, 250 males and 314 females
aged 20-75 yr, were enrolled during routine health evalua-
tions at the Tri-Service General Hospital between 1995 and
1999. The demographic data derived from the subjects are
shown in Table 1. Subjects with a history of diabetes, hyper-
tension, hyperlipidemia, or other significant medical or sur-
gical diseases were excluded. Subjects who were placed on
medications which affect insulin sensitivity were also exclud-
ed from the study. 
The study was approved by the Hospital Ethics Commit-
tee, and the nature, purpose, and potential risks of the study
were explained to the patients before obtaining their consent
to participate. Since Reaven suggested that the upper 25%
in the general population are IR, we divided our subjects into
four groups regarding each of five clinical characteristics of
the MetS and then evaluated the IR in each quartile (2).
Laboratory evaluation
The ability of insulin to dispose of a glucose load was esti-
mated by modification of the IST, as described by Shen et al.
(10). After an overnight fast, intravenous catheters were intro-
duced in the arms of each subject. One catheter was used for
the administration of a 180 min infusion of somatostatin (250
g/hr), insulin (25 mU/m2/min), and glucose (240 mg/m2/
min). The other arm was used for the collection of blood
samples. Blood was collected every 30 min initially, and then
at 10 min intervals from 150-180 min of the infusion, to
determine the steady state plasma insulin (SSPI) and SSPG
concentrations for each individual. The SSPI concentrations
were comparable in all individuals, thus the SSPG concentra-
tions provided the measure of efficacy of insulin in promot-
ing disposal of the infused glucose load.
Plasma was separated from blood within 1 hr and stored at
-30℃ until analyzed. The samples obtained at -5 and 0 min
were analyzed for fasting plasma glucose (FPG), fasting plas-
ma insulin (FPI), and lipid levels. Plasma glucose levels were
determined using the glucose oxidase method (YSI 203 Glu-
cose Analyzer; Scientific Division, Yellow Spring Instrument
Company, Inc., Yellow Spring, OH, U.S.A.). Insulin levels
were measured by a commercial solid phase radioimmunoas-
say kit (11; Coat-A-Count Insulin Kit; Diagnostic Products
Corporation, Los Angeles, CA, U.S.A.). The intra- and inter-
assay coefficients of variance for insulin were 3.3% and 2.5%,
respectively. Both triglyceride (TG) and total cholesterol (TC)
levels were measured using the dry, multilayer analytical slide
method in the Fuji Dri-Chem 3000 analyzer (Fuji Photo
Film Corporation, Minato-Ku, Tokyo, Japan). Serum high
density lipoprotein cholesterol (HDLC) concentration was
determined by an enzymatic, cholesterol assay method fol-
lowing dextran sulfate precipitation. 
Statistical analysis
Analysis was performed using SPSS for Windows, version
10.0 (SPSS; Chicago, IL, U.S.A.). Data were tested for nor-
mal distribution using the Kolmogorov-Smirnov test and
for homogeneity of variances with Levene’s test. Continuous
variables are expressed as the mean±SEM. Independent Stu-
dent’s t-test was used to evaluate gender-based physical and
metabolic differences. The one-way ANOVA with the Bon-
ferroni method as a post hoc test was also applied to compare
differences between the clinical characteristics in each quar-
tile. Since age was considered as the confounding covariate, each
variable of interest (i.e., body mass index [BMI], TG, HDLC,
FPG, and blood pressure) was first adjusted for age by emp-
loying the analysis of covariance. The derived residuals (adjust-
ed variables) were then again used for analyses after the unad-
justed data were examined. All statistical tests were two-sided
and p-values less than 0.05 were considered to indicate sta-
tistical significance. Furthermore, exploratory factor analysis
was conducted to examine the relationships among the vari-
ables which constituted MetS. Principle factor analysis was
employed to transform the original variables into a new set
of components which are independent of each other. Then
Total Male Female
Subject number 564 250 314
Age (yr) 45.7±0.5 45.9±0.8 45.6±0.7
BMI (kg/m
2)2 4 ±0.2 24.3±0.2 23.8±0.2
SBP (mmHg) 118.7±0.7 121.1±1* 116.8±0.9
DBP (mmHg) 76.8±0.4 78.5±0.6* 75.5±0.5
FPG (mM/L) 5.7±0.1 5.7±0.1 5.6±0.6
TC (mM/L) 4.37±0.04 4.32±0.07 4.39±0.06
HDL-C (mM/L) 1.06±0.02 1±0.02* 1.1±0.02
TG (mM/L) 1.59±0.04 1.67±0.06 1.54±0.05   
Table 1. The baseline characteristics in subjects of both genders
Data are means±SEM. BMI, body mass index; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC,
total cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyc-
erides. *p<0.05 vs. female after adjusted for age, sex and BMI.76 C.-H. Hsieh, Y.-J. Hung, D.-A. Wu, et al.
number of components to be retained was based on Scree plot
analysis (factors above the break in the curve were retained)
and eigenvalue criteria (1.0). Such two modalities have been
adopted to identify the minimum number of components
(8, 12, 13). Varimax rotation was used to obtain a set of inde-
pendent and interpretable factors. The resulting factor pat-
tern was interpreted using factor loadings of ≥0.4. We only
put the factors of the MetS and SSPG into the model. 
RESULTS 
As expected, the male subjects in the current study had
higher blood pressures and lower HDLC levels than the female
subjects. The other MetS clinical characteristics measured
did not differ significantly between male and female subjects
(Table 1).
We further divided the male and female subjects into quar-
tiles according to the measured levels of each MetS clinical
characteristic, with subjects in the upper quartile having the
highest levels and those in the lower quartile having the low-
est levels. In the current study, we used two different meth-
ods to evaluate the importance of IR with respect to the MetS.
First, we compared the SSPG quartiles within individual MetS
clinical characteristics. Then, since there were six mean SSPG
values derived from each clinical characteristic (i.e., BMI, sys-
tolic blood pressure [SBP], diastolic blood pressure [DBP],
FPG, TG, and HDLC), we further compared the SSPG val-
ues derived from all clinical characteristics. 
The results of comparisons of the four quartiles for males
and females are shown in Fig. 1, 2, respectively. In males, the
upper quartiles from the BMI and FPG clinical characteris-
tics had the highest SSPG levels as compared to the other
three quartiles. The upper quartiles of the DBP and TG clini-
cal characteristics were only greater than the lower two quar-
tiles. In females, the SSPG levels in the upper quartile of the
BMI and TG clinical characteristics were significantly greater
than the other lower three quartiles. While the SSPG levels
were highest in the SBP and FPG clinical characteristics, they
were only higher than the third quartile (Fig. 2).
In order to evaluate which of the highest quartiles repre-
senting any of the MetS clinical characteristics had the high-
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Fig. 2. The insulin resistance of different quartiles in each metabolic
syndrome component among female subject.
Data are means±SEM. BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure; FPG, fasting plasma
glucose; TG, triglycerides; HDL-C, high density lipoprotein choles-
terol; SSPG, steady-state plasma glucose. *p<0.05 after adjusted
for age.
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Fig. 1. The insulin resistance of different quartiles in each metabolic
syndrome component among male subjects.
Data are means±SEM. BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure; FPG, fasting plasma glu-
cose; TG, triglycerides; HDL-C, high density lipoprotein choles-
terol; SSPG, steady-state plasma glucose. *p<0.05 after adjust-
ed for age.
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est SSPG levels, we further compared the upper quartiles of
the BMI, SBP, DBP, FPG, HDLC, and TG clinical charac-
teristics. No significance was found with respect to gender
(Fig. 3), except the SSPG level was greater in the upper quar-
tile of the BMI clinical characteristic than in the upper quar-
tile of the HDLC clinical characteristic (12.37±0.47 vs. 9.52
±0.52 mM/L, respectively) in males (Fig. 3).
Finally, Table 2 displays the results of factor analysis of core
metabolic variables among the study subjects. Fig. 4 graph-
ically depicts the same results with the percentage of variance
explained by each factor. A two-factor solution, which was
supported by the retention criteria described in the method,
was obtained. These factors could be interpreted as 1) a ‘‘in-
sulin resistance’’ factor, with a positive loading of BMI, FPG,
TG, SSPG and an inverse loading of HDLC, and 2) a ‘‘blood
pressure’’ factor with a positive loading of BMI and both the
SBP and DBP. The two-factor solution explained about 56%
of the total variance in these subjects (28.4% factor 1 and
27.3% factor 2).
DISCUSSION
The data herein showed that, in general, the trend of higher
SSPG levels was associated with more MetS clinical charac-
teristics (Fig. 1, 2). However, only the BMI, FPG, and TG
in both males and females, DPB in males, and SBP in females
had significantly higher SSPG levels in the upper quartile
as compared to the lower quartiles. These results suggested
that among the five clinical characteristics of the MetS mea-
sured, BMI, FPG, and TG might be best related to IR and
therefore, are the first clinical characteristics to be detected
as abnormal. Similar findings have been reported by others.
For example, Cheal et al. found that among all the MetS clin-
ical characteristics, BMI and TG were best correlated with
SSPG (14). By using factor analysis to evaluate the relation-
ships between MetS clinical characteristics and IR, Meigs et
al. also arrived at the same conclusion. Thus, he further sug-
gested that IR should be the central focus in assessing the
MetS (8). 
The significant effect BMI had on IR in our study was not
surprising. It has been long-recognized that IR is clearly asso-
ciated with obesity, whether generalized or central (15-17).
The detrimental influence of central adiposity on IR is tho-
ught to be mediated by intra-abdominal fat deposition, in
which hypertrophied adipocytes are resistant to anti-lipolytic
Communalities Risk factors Factor 1 Factor 2
Body mass index 0.445 0.529 0.406
Systolic blood pressure 0.796 0.078 0.889
Diastolic blood pressure 0.811 0.118 0.893
Fasting plasma glucose 0.376 0.593 0.158
Steady state plasma glucose 0.578 0.711 0.269
Triglycerides 0.534 0.726 0.078
High density lipoprotein  0.357 -0.548 0.237
cholesterol
Table 2. Results of factor analysis with risk factors, including
directly measured insulin resistance from the insulin suppres-
sion test
Loadings ≥0.40 in bold type.
*
S
S
P
G
 
(
m
M
/
L
)
16
12
8
4
0
BMI SBP DBP FPG TG HDL-C
Male
Fig. 3. The comparison of steady state plasma glucose of group 1 of each metabolic syndrome components in both genders. The steady
state plasma glucose are from group 1 in different metabolic syndrome components. Data are means±SEM. BMI, body mass index; SBP,
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Fig. 4. A diagrammatic representation of factor analysis performed
in study subjects. FPG, fasting plasma glucose; SSPG, steady
state plasma glucose; TG, triglycerides; HDLC, high density lipo-
protein cholesterol; BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure.    , positive loading;    ,
negative loading. The numbers shown are the percentage of ex-
plained variance of either each factor or the sum of the factors.
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action of insulin. As a consequence, elevated levels of free fatty
acids may induce IR in the peripheral tissues and liver (18).
Also, the preponderance of enlarged fat cells, as occur in ab-
dominal obesity, may increase the risk of glucose intolerance
and hypertriglyceridemia and thus account for the metabol-
ic derangements (19, 20).
It is interesting to note that the relationships between IR
and some of the MetS clinical characteristics were affected
by gender. In our study, for example, the upper quartile of
DBP in males had significantly higher SSPG levels than the
lower three quartiles. In contrast, instead of DBP, the SSPG
was higher in the upper quartile of SBP in females. These
results suggested that the relationships between blood pres-
sure and SSPG were less consistent in our study. It is difficult
to meaningfully compare this finding with other reports, since
most of the other reports adjusted both sex and age when
discussing the relationships between blood pressure and IR
(17, 21, 22). Other than blood pressure, the relationships
between IR and HDLC were also different between the gen-
ders. Fig. 1, 2 show that the levels of SSPG did not differ bet-
ween any quartiles representing the HDLC clinical charac-
teristic. However, as illustrated in Fig. 3, when comparing
the upper quartiles of all the MetS clinical characteristics, the
upper quartile of the HDLC clinical characteristic had the
lowest SSPG level, but was only significant in males. It is
well-recognized that IR is related to high TG and low HDLC
(23, 24); however, most of these reports showed that gender
had no effect on the relationships involving IR. Nevertheless,
some reports did demonstrate a gender effect. For example,
Mykkanen et al. found that IR was more strongly related to
HDLC in males than females, as evidenced by the intravenous
glucose tolerance test (24). This unique finding was further
confirmed in another study conducted in subjects with mor-
bid obesity. The correlations between IR and TG or HDLC
were stronger in males than in females (25). These data are
consistent with the findings reported herein. Since both HD-
LC and SBP were shown to be related to SSPG levels in males,
our data further imply that males might be more prone to
develop MetS when in middle age, as suggested by Cook et
al. (26). At present, there are two possibilities to explain the
metabolic differences which existed between males and females
in our study. First, IR may be increased by sex hormones (27).
This in turn will further increase the risk of cardiovascular
disease and diabetes (28, 29). Second, male subjects tend to
have more upper truncal adiposity (i.e., a higher waist-to-hip
ratio [WHR]) than female subjects. In the current study, since
we observed differences between each MetS clinical character-
istic, we did not adjust the effect of BMI on other risk factors,
which is a departure from other studies (23-25).
It is generally agreed that there is a positive correlation
between blood pressure and IR. Using the euglycemic insulin
clamp, this relationship has been repeatedly demonstrated
in many different studies (17, 21, 22). For instance, Ferran-
nini et al. reported that male gender, age, and IR were inde-
pendently associated with SBP, whereas DBP was related to
age, IR, and FPI, but not to the BMI (17). They also found
that DBP had a higher correlation with IR than SBP (r=0.34
and 0.18, respectively). However, the same conclusion was
not always reached in studies involving other ethnic groups
(30) and the relationships did not exist when adjusted for
body fat content (31). The discrepancies of these results may
be due to the fact that blood pressure per se is not clustered
with IR. Other possibilities such as the different ethnic groups
or the methods used to measure adiposity might also play a
role. In the Ferrannini et al. study, and as done herein, BMI
was used to quantify adiposity. At the same time, Toft et al.
used WHR and suggested that in subjects with the same
BMI, changes in WHR may still influence the results of vari-
ables associated with insulin sensitivity because the accumu-
lation of visceral fat leads to altered insulin clearance (31). In
the Peiris et al. study, the clearance rates of insulin were sim-
ilar between obese and non-obese subjects (32); however, it
was inversely correlated with the WHR in obese subjects.
Therefore, Peiris et al. pointed out that WHR is better asso-
ciated with diminished insulin clearance than BMI (32).
It has been shown that the homeostasis model assessment
of IR (HOMA-IR; 33, 34), which is calculated from FPG
and FPI, is a useful surrogate for IR in healthy and diabetic
subjects. It has proven to be highly correlated with the gold
standard, the euglycemic hyperinsulinemic clamp (33). At
present, it is generally recognized that one of the main under-
lying pathophysiologies of glucose intolerance is IR. How-
ever, in subjects who already have IR, due to the compensato-
ry increased secretion of the insulin, the FPG may persist
within the normal range. That is why the study done by Hol-
lenbeck and Reaven showed that there was no relationship
found between FPG and IR (35). On the contrary, the cor-
relation between FPI and IR was significant in normal glu-
cose tolerance subjects. Surprisingly, in our study, the SSPG
seemed to be higher as the FPG increased. This finding sug-
gested that even in the early stages before MetS develops,
FPG is already elevated in subjects with an elevated IR.
The results of the factor analysis are similar to most of the
other studies. In these studies, usually there are three to four
factors being identified; the ‘‘insulin resistant factor’’, ‘‘obese
factor’’, ‘‘lipid factor’’, and/or ‘‘blood pressure factor’’ (8, 9, 13,
36-39). To the present, one of the most important studies
using factor analysis to explore the relationship between IR
and other common risk factors for cardiovascular diseases was
published by Hanley et al. (40). Instead of SSPG, they have
used the intravenous glucose tolerance test to evaluate insulin
sensitivity (SI). They have also identified two factors in the
IGT and NGT subjects: the ‘‘metabolic factor’’ (comprising
BMI, waist, SI, TG, and HDLC); and the ‘‘blood pressure fac-
tor’’. The only differences are FPG was not loaded in factor
1 and BMI was not loaded in factor 2. It could be noted that
the clustering patterns in our study were not only similar to
Hanley’s study (40) but also to the most of other studies withMetabolic Syndrome Clinical Characteristics and Insulin Resistance 79
different severities of impaired glucose metabolism and eth-
nic groups (13, 36, 38, 39). The clustering of the SSPG, BMI,
FPG and TG could further confirm that the IR is more cor-
related with lipids profile and BMI, but less with the blood
pressure. BMI is loaded in both factor also suggested its im-
portance in the MetS.
It should be noted and emphasized that this was a hospi-
tal-based cohort study. A population-based study should be
conducted to further confirm our findings. However, the pur-
pose of this study was to observe the relationships between
IR and MetS, thus, this drawback should not affect the con-
clusions drawn from the present study. Our data suggested
that adiposity, higher FPG, and hypertriglyceridemia are more
strongly associated with IR in Chinese subjects and the im-
portance of these clinical characteristics should be reempha-
sized. This conclusion could also be supported by the results
of factor analysis. When considering each of the MetS clini-
cal characteristics, subjects with a higher BMI may have the
highest IR.
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